Principal Financial Group Inc. Has $29.33 Million Stake in Bruker Co. (NASDAQ:BRKR)

Principal Financial Group Inc. grew its position in Bruker Co. (NASDAQ:BRKRGet Rating) by 3,212.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 349,552 shares of the medical research company’s stock after buying an additional 338,999 shares during the quarter. Principal Financial Group Inc. owned 0.23% of Bruker worth $29,331,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of BRKR. Morgan Stanley raised its position in shares of Bruker by 340.3% in the 2nd quarter. Morgan Stanley now owns 198,141 shares of the medical research company’s stock valued at $15,055,000 after buying an additional 153,140 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its position in shares of Bruker by 42.8% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 6,834 shares of the medical research company’s stock valued at $534,000 after buying an additional 2,048 shares in the last quarter. PNC Financial Services Group Inc. raised its position in shares of Bruker by 24.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 900 shares of the medical research company’s stock valued at $70,000 after buying an additional 178 shares in the last quarter. Advisor Group Holdings Inc. raised its position in shares of Bruker by 6.5% in the 3rd quarter. Advisor Group Holdings Inc. now owns 30,108 shares of the medical research company’s stock valued at $2,353,000 after buying an additional 1,844 shares in the last quarter. Finally, JustInvest LLC raised its position in shares of Bruker by 6.2% in the 3rd quarter. JustInvest LLC now owns 3,424 shares of the medical research company’s stock valued at $267,000 after buying an additional 201 shares in the last quarter. Institutional investors own 76.09% of the company’s stock.

BRKR opened at $60.21 on Friday. Bruker Co. has a fifty-two week low of $55.80 and a fifty-two week high of $92.35. The company has a debt-to-equity ratio of 1.17, a current ratio of 2.56 and a quick ratio of 1.70. The firm has a market capitalization of $8.99 billion, a price-to-earnings ratio of 32.37, a PEG ratio of 1.31 and a beta of 1.26. The company’s 50 day moving average price is $62.76 and its two-hundred day moving average price is $71.03.

Bruker (NASDAQ:BRKRGet Rating) last posted its earnings results on Wednesday, May 4th. The medical research company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.07. Bruker had a net margin of 11.47% and a return on equity of 31.16%. The firm had revenue of $595.00 million for the quarter, compared to analyst estimates of $572.50 million. During the same period in the previous year, the firm posted $0.44 EPS. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. As a group, equities research analysts predict that Bruker Co. will post 2.31 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, March 18th. Shareholders of record on Tuesday, March 1st were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.33%. This is a positive change from Bruker’s previous quarterly dividend of $0.04. The ex-dividend date was Monday, February 28th. Bruker’s payout ratio is presently 10.75%.

Several brokerages have recently commented on BRKR. StockNews.com assumed coverage on shares of Bruker in a research report on Thursday, March 31st. They issued a “buy” rating for the company. Zacks Investment Research lowered shares of Bruker from a “buy” rating to a “hold” rating and set a $64.00 price target on the stock. in a report on Tuesday, April 19th. The Goldman Sachs Group decreased their price target on shares of Bruker from $73.00 to $60.00 and set a “sell” rating on the stock in a report on Wednesday, April 13th. Finally, SVB Leerink lifted their price target on shares of Bruker from $84.00 to $85.00 and gave the company an “outperform” rating in a report on Monday, February 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $76.50.

About Bruker (Get Rating)

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies.

Featured Stories

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.